BioLineRx Ltd.
BioLineRx Ltd. is a commercial stage biopharmaceutical company developing therapeutics for oncology and rare diseases. Its pipeline includes APHEXDA (motixafortide) in Phase 1 clinical trials for sickle cell disease and pancreatic cancer, as well as completed Phase 3 trial for multiple myeloma.
Overview
Strengths
- Paying down debt: long-term debt fell by 12.1 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 6.8% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 41.4% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data